0.11
0.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vaxil Bio
Its shares trade on TSX Venture under the ticker VXL.V. It has been listed since 2 March 2011.
Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-03-02. The firm is focused on a novel drug discovery and development platform based on signal peptides (SPs) to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, is a MUC1 SP-derived vaccine, which completed a Phase I/II clinical trial in multiple myeloma. The firm also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. The firm has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. The firm exploits the unique properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Mar 2011
Leadership
Pay as last reported
- Mr. Gadi LevinChairman of the Board, Chief Executive Officer, since 2016C$60,000
- Mr. Alan RootenbergChief Financial Officer
- Dr. Ari KellenIndependent Director
- Dr. Shawn LangerIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vaxil Bio Ltd. develops neoantigen-like peptide products for cancer treatment in Toronto, Ontario.
- ImMucin, a MUC1 SP-derived vaccine, completed Phase I/II trials in multiple myeloma.
- Vaxil Bio Ltd. has SP-based vaccine candidates for COVID-19 and tuberculosis in development.
Weaknesses
- Vaxil Bio Ltd. has no approved products for cancer or infectious diseases as of 2023.
- The company's SP-based drug discovery platform requires further clinical validation.
- Vaxil Bio Ltd. relies on licensing from BGN Technologies for P-Esbp development.
Opportunities
- Vaxil Bio Ltd. can expand its SP-based vaccine candidates into new markets like Asia-Pacific.
- The growing biotechnology sector in Canada offers opportunities for Vaxil Bio Ltd. growth.
- Vaxil Bio Ltd. may partner with pharmaceutical companies to accelerate clinical trials.
Threats
- Vaxil Bio Ltd. faces competition from established biotech firms in the Health Care sector.
- Regulatory delays could impact the approval of Vaxil Bio Ltd.'s SP-based therapies.
- Vaxil Bio Ltd. depends on clinical trial success for its SP-based products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.